Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
not exceed,6295106,maximum inhibition,LA 2851 and theophylline did not inhibit all the components of the inflammatory process since maximum inhibition did not exceed 60% up to 200 mg/kg and 100 mg/kg respectively.,Anti-inflammatory effect of LA 2851 and reference drugs on some models of inflammation. Investigation of the mechanism of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6295106/),%,60,942,DB01113,Papaverine
,7295412,bioavailability,Only one of the three chronoid preparations had appropriately delayed bioavailability 89% in comparison to normal acting formulation.,Papaverine bioavailability in delayed absorption formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295412/),%,89,6937,DB01113,Papaverine
,1513193,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 102.4%, 9.1%, and 12.4%, respectively, following intracorporeal injection, gel PT and gel PTL administration.","Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513193/),%,102.4,7663,DB01113,Papaverine
,1513193,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 102.4%, 9.1%, and 12.4%, respectively, following intracorporeal injection, gel PT and gel PTL administration.","Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513193/),%,9.1,7664,DB01113,Papaverine
,1513193,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 102.4%, 9.1%, and 12.4%, respectively, following intracorporeal injection, gel PT and gel PTL administration.","Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513193/),%,12.4,7665,DB01113,Papaverine
,11922744,urine output,In the control group the mean urine output was 0.015 ml/min/kg and the mean creatinine clearance was 0.95 ml/min/kg.,Periarterial papaverine application improves intraoperative kidney function during laparoscopic donor nephrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922744/),[ml] / [kg·min],0.015,13785,DB01113,Papaverine
,11922744,urine output,In pigs treated with papaverine the mean urine output was 0.052 ml/min/kg and the mean creatinine clearance was 2.22 ml/min/kg.,Periarterial papaverine application improves intraoperative kidney function during laparoscopic donor nephrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11922744/),[ml] / [kg·min],0.052,13786,DB01113,Papaverine
,26642661,flow rate,"Chromatographic separation of DIC, PAP and the IS was achieved on a Zorbax SB C18 5-µm column (150 mm x 4.6 mm) using methanol-water (55:45, v/v) as mobile phase at a flow rate of 0.8 mL/min.",PHARMACOKINETICS OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE AFTER ORAL ADMINISTRATION OF TABLETS TO RABBITS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642661/),[ml] / [min],0.8,17050,DB01113,Papaverine
,8120119,signal-to-noise ratio,The lowest limit of detection (signal-to-noise ratio 3:1) was 6 ng/ml.,High-performance liquid chromatographic method for the determination of drotaverine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120119/),[ng] / [ml],3:1,18241,DB01113,Papaverine
,8120119,signal-to-noise ratio,The lowest limit of detection (signal-to-noise ratio 3:1) was 6 ng/ml.,High-performance liquid chromatographic method for the determination of drotaverine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120119/),[ng] / [ml],6,18242,DB01113,Papaverine
,3413033,bioavailability,The bioavailability of the drug was highly variable with a mean of 28% (range 5-99%) but reproducible within the same individual (4 of the volunteers) after a repeated (80 mg) oral dose.,Variable bioavailability of papaverine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413033/),%,28,20397,DB01113,Papaverine
,3413033,half-life,The calculated half-life after intravenous administration ranged between 1.2-6.6 hours (mean 3.0).,Variable bioavailability of papaverine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413033/),h,3.0,20398,DB01113,Papaverine
,3413033,apparent volume of distribution,The mean apparent volume of distribution was 3.1 l/kg and the mean total plasma clearance was 836 ml/min.,Variable bioavailability of papaverine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413033/),[l] / [kg],3.1,20399,DB01113,Papaverine
,3413033,total plasma clearance,The mean apparent volume of distribution was 3.1 l/kg and the mean total plasma clearance was 836 ml/min.,Variable bioavailability of papaverine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413033/),[ml] / [min],836,20400,DB01113,Papaverine
,16500065,flow rate,"The analysis was carried out on a Lichrospher-CN column (250 mmx4.6 mm, i.d., 5 microm, Merck) with mobile phase of methanol-ammonium acetate (20 mmol/l; 85:15, v/v) pumped at a flow rate of 1.0 ml/min.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[ml] / [min],1.0,28315,DB01113,Papaverine
,16500065,LOD,"The assay was validated to be accurate and precise for the analysis in the concentration range of 1.0-40,000 ng/ml for both OMT and MT with the LOD being 0.5 and 0.2 ng/ml, respectively, when 0.25 ml of human plasma sample was processed with papaverine as internal standard.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[ng] / [ml],0.5,28316,DB01113,Papaverine
,16500065,LOD,"The assay was validated to be accurate and precise for the analysis in the concentration range of 1.0-40,000 ng/ml for both OMT and MT with the LOD being 0.5 and 0.2 ng/ml, respectively, when 0.25 ml of human plasma sample was processed with papaverine as internal standard.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[ng] / [ml],0.2,28317,DB01113,Papaverine
,16500065,Cmax,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[ng] / [ml],"20,519",28318,DB01113,Papaverine
,16500065,Cmax,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[ng] / [ml],247,28319,DB01113,Papaverine
,16500065,Tmax,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),h,0.5,28320,DB01113,Papaverine
,16500065,Tmax,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),h,5.6,28321,DB01113,Papaverine
,16500065,AUC0-t,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[h·ng] / [ml],"20,360",28322,DB01113,Papaverine
,16500065,AUC0-t,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[h·ng] / [ml],3817,28323,DB01113,Papaverine
,16500065,AUC0-infinity,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[h·ng] / [ml],"20,436",28324,DB01113,Papaverine
,16500065,AUC0-infinity,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[h·ng] / [ml],3841,28325,DB01113,Papaverine
,16500065,t1/2,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),h,2.17,28326,DB01113,Papaverine
,16500065,t1/2,"The main pharmacokinetic parameters found for OMT and MT after i.v. infusion were as follows: Cmax (20,519+/-7581) and (247+/-45) ng/ml, Tmax (0.5+/-0.1) and (5.6+/-1.7) h, AUC0-t (20,360+/-5205) and (3817+/-610) ng h/ml, AUC0-infinity (20,436+/-5188) and (3841+/-615) ng h/ml, t1/2 (2.17+/-0.49) and (9.43+/-0.62) h, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),h,9.43,28327,DB01113,Papaverine
,16500065,CL/F,"The CL/F and Vd/F of OMT were (43.8+/-10.8) l h-1 and (70.1+/-26.6) l, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),[l] / [h],43.8,28328,DB01113,Papaverine
,16500065,Vd/F,"The CL/F and Vd/F of OMT were (43.8+/-10.8) l h-1 and (70.1+/-26.6) l, respectively.",Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16500065/),l,70.1,28329,DB01113,Papaverine
,14522031,flow rate,"Chromatographic separation was achieved using a microbore C-18 column and a mobile phase consisting of 0.1% aqueous trifluoroacetic acid (TFA)-acetonitrile (75:25% (v/v)), pH 2.2, at a flow rate of 0.07 ml/min.",Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522031/),[ml] / [min],0.07,54066,DB01113,Papaverine
,19662624,run time,"The analyte (henatinib maleate) and internal standard (papaverine hydrochloride) were extracted from 50 microL of rat plasma by protein precipitation and separated on a C(18) column using a mixture of 25 mm ammonium acetate buffer : methanol : acetonitrile (35 : 50 : 15, v/v/v) as mobile phase with a run time of 4.5 min.","Quantification of henatinib maleate, a novel potent inhibitor of VEGF receptors, in rat plasma by LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19662624/),min,4.5,60269,DB01113,Papaverine
,30081350,flow rate,"These four components were separated using water containing 0.01% formic acid and methanol as a mobile phase by gradient elution at a flow rate of 0.3 mL/min with a HALO-C18 column (2.1 mm × 100 mm, 2.7 μm particle size).",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),[ml] / [min],0.3,87010,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,432.9,87011,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,384.1,87012,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,165.8,87013,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,525.0,87014,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,146.8,87015,DB01113,Papaverine
,30081350,Mass transitions,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,340.0,87016,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,432.9,87017,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,384.1,87018,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,165.8,87019,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,148.1,87020,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,525.0,87021,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,449.2,87022,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,146.8,87023,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,102.9,87024,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,340.0,87025,DB01113,Papaverine
,30081350,m/z,"Mass transitions were m/z 432.9 → 384.1 for schizandrin, 165.8 → 148.1 for ephedrine, 525.0 → 449.2 for paeoniflorin, 146.8 → 102.9 for cinnamic acid, and 340.0 → 324.0 for papaverine as internal standard.",Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081350/),,324.0,87026,DB01113,Papaverine
,7767316,half-life,"The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7% ID/g) at 5 min, followed by clearance with a half-life of 16.1 min.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),min,16.1,112974,DB01113,Papaverine
,7767316,ratio,"As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),,7.4,112975,DB01113,Papaverine
,7767316,ED50,[11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum.,[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),[mg] / [kg],0.3,112976,DB01113,Papaverine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,120,127131,DB01113,Papaverine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,83,127132,DB01113,Papaverine
,1881016,maximum serum concentration,"The maximum serum concentration of papaverine measured after intracavernous injection was 7.7 ng/ml, which was considerably lower than the average serum concentration of 24.0 ng/ml after intravenous injection.",[The meanings of the papaverine test]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881016/),[ng] / [ml],7.7,142337,DB01113,Papaverine
,649238,apparent half lives,"The pharmacokinetics of completely metabolized papaverine hydrochloride were characterized by a linear sum of three exponentials on intravenous administration with respective 1.5, 19 and 107 min apparent half lives.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,1.5,144534,DB01113,Papaverine
,649238,apparent half lives,"The pharmacokinetics of completely metabolized papaverine hydrochloride were characterized by a linear sum of three exponentials on intravenous administration with respective 1.5, 19 and 107 min apparent half lives.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,19,144535,DB01113,Papaverine
,649238,apparent half lives,"The pharmacokinetics of completely metabolized papaverine hydrochloride were characterized by a linear sum of three exponentials on intravenous administration with respective 1.5, 19 and 107 min apparent half lives.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,107,144536,DB01113,Papaverine
,649238,apparent half life,There was a time-dependent partition from plasma water into red blood cells with an apparent half life of 1.5--3 min.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,1,144537,DB01113,Papaverine
,649238,partition coefficient,The partition coefficient normally ranged between 8 and 15 at therapeutic levels but approached unity at high plasma concentrations to indicate a saturable partition.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),,8 and 15,144538,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,4.3,144539,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,4.8,144540,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,11,144541,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,13,144542,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,20,144543,DB01113,Papaverine
,649238,Apparent compartmental volumes of distribution,"Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),l,25,144544,DB01113,Papaverine
,649238,Protein binding,Protein binding was 91--95%.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,91,144545,DB01113,Papaverine
,649238,Protein binding,Protein binding was 91--95%.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,95,144546,DB01113,Papaverine
,649238,hepatic clearance of blood,"The hepatic clearance of blood was 960 ml/min, corresponding to a hepatic efficiency of 69%, and indicated that the clearance of protein-bound drug was consistent with the observed first pass metabolism of 70% for oral solutions.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),[ml] / [min],960,144547,DB01113,Papaverine
,649238,hepatic efficiency,"The hepatic clearance of blood was 960 ml/min, corresponding to a hepatic efficiency of 69%, and indicated that the clearance of protein-bound drug was consistent with the observed first pass metabolism of 70% for oral solutions.",Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,69,144548,DB01113,Papaverine
,649238,release lag times,Tablets with release lag times of 10--15 min showed relative bioavailabilities of 52%.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,10--15,144549,DB01113,Papaverine
,649238,relative bioavailabilities,Tablets with release lag times of 10--15 min showed relative bioavailabilities of 52%.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,52,144550,DB01113,Papaverine
,649238,relative bioavailabilities,Two different lots of sustained release capsules showed 68 and 89% relative bioavailabilities.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,68,144551,DB01113,Papaverine
,649238,relative bioavailabilities,Two different lots of sustained release capsules showed 68 and 89% relative bioavailabilities.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),%,89,144552,DB01113,Papaverine
,649238,Release lag times,Release lag times among capsules ranged between 0 and 170 min.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,0 and 170,144553,DB01113,Papaverine
,649238,half life of absorption,Loo-Riegelman calculations and analog computer fittings were consistent with a half life of absorption from oral solutions of 19 min and zero order release rates from tablets and sustained release capsules.,Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/649238/),min,19,144554,DB01113,Papaverine
,873666,biological half-life,"The biological half-life of papaverine varies between 1.5 and 2.2 hours, and has a volume of distribution of approximately 15% of the body weight.",Pharmacokinetics of papaverine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/873666/),h,1.5 and 2.2,150022,DB01113,Papaverine
,20447563,IC(50),"Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.","Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447563/),nM,36,166394,DB01113,Papaverine
,20447563,IC(50),"Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.","Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447563/),nM,"1,300",166395,DB01113,Papaverine
,20447563,IC(50),"Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.","Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447563/),nM,320,166396,DB01113,Papaverine
>,20447563,specific activity,[(11)C]papaverine was obtained with approximately 70% radiochemical yield and a specific activity >10 Ci/mumol.,"Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447563/),[ci] / [μM],10,166397,DB01113,Papaverine
,32992211,flowrate,"The flowrate was of 0.15 ml/min, detector wavelength was set at 360 nm for GRS and at 230 nm for papaverine (IS).",Development and validation of HPLC-UV method for quantitation of a new antithrombotic drug in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32992211/),[ml] / [min],0.15,174610,DB01113,Papaverine
,32992211,recovery,"It was found that GRS recovery from rat plasma is 94%, the response linearity is in the range of 10 to 1000 ng ml-1.",Development and validation of HPLC-UV method for quantitation of a new antithrombotic drug in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32992211/),%,94,174611,DB01113,Papaverine
,8158764,half-time,"Measurement of the primary metabolite proves a local degradation of prostaglandin E1 in the corpus cavernosum into the biologically inactive 15-keto-13,14-dihydro-prostaglandin E1, which also shows a slight increase in the peripheral circulation due to the longer half-time of approximately 8 minutes.",Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158764/),min,8,177596,DB01113,Papaverine
,9415209,Cmax,"Potato starch-PEG 4000, potato starch-MSG, NaCMC-PEG 1500 spheres show best F-parameters of papaverine respectively 96%, 89%, 88%, Cmax 19.7, 21.3, 18.6 micrograms/ml reached in about 2 h.",Effect of carriers and hydrophilic agents on papaverine spheres bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9415209/),[μg] / [ml],19.7,179820,DB01113,Papaverine
,9415209,Cmax,"Potato starch-PEG 4000, potato starch-MSG, NaCMC-PEG 1500 spheres show best F-parameters of papaverine respectively 96%, 89%, 88%, Cmax 19.7, 21.3, 18.6 micrograms/ml reached in about 2 h.",Effect of carriers and hydrophilic agents on papaverine spheres bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9415209/),[μg] / [ml],21.3,179821,DB01113,Papaverine
,9415209,Cmax,"Potato starch-PEG 4000, potato starch-MSG, NaCMC-PEG 1500 spheres show best F-parameters of papaverine respectively 96%, 89%, 88%, Cmax 19.7, 21.3, 18.6 micrograms/ml reached in about 2 h.",Effect of carriers and hydrophilic agents on papaverine spheres bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9415209/),[μg] / [ml],18.6,179822,DB01113,Papaverine
,15212193,limit of detection,The limit of detection was 6 ng/ml.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],6,210142,DB01113,Papaverine
,15212193,AUC(0-infinity),Values of 1593.92 +/- 949.70 ng x h/l (95% confidence interval (CI): 1183.20-2004.60) for the test and 1705.48 +/- 737.78 ng x h/l (95% CI: 1386.40-2024.50) for the reference preparation AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[h·ng] / [l],1705.48,210143,DB01113,Papaverine
,15212193,Maximum concentrations--Cmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],121.89,210144,DB01113,Papaverine
,15212193,Maximum concentrations--Cmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],121.85,210145,DB01113,Papaverine
,15212193,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),h,1.29,210146,DB01113,Papaverine
,15212193,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),h,1.14,210147,DB01113,Papaverine
,15212193,relative bioavailability (AUC(0-infinity) ratio,"The relative bioavailability (AUC(0-infinity) ratio test/reference) and Cmax ratio test/reference were 103.15% (90% CI: 81.68-124.60) and 103.74% (90% CI: 94.10-113.38), respectively.",Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),%,103.15,210148,DB01113,Papaverine
,15212193,relative bioavailability (AUC(0-infinity) ratio,"The relative bioavailability (AUC(0-infinity) ratio test/reference) and Cmax ratio test/reference were 103.15% (90% CI: 81.68-124.60) and 103.74% (90% CI: 94.10-113.38), respectively.",Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),%,103.74,210149,DB01113,Papaverine
,6499894,elimination half-life,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),h,1.30,210351,DB01113,Papaverine
,6499894,total plasma clearance,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[ml] / [kg·min],13.8,210352,DB01113,Papaverine
,6499894,volume of distribution,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[l] / [kg],1.52,210353,DB01113,Papaverine
,6499894,"volume of distribution, steady-state,","Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[l] / [kg],0.992,210354,DB01113,Papaverine
,6499894,half-life,"For the CPB group, only half-life was estimated, and averaged 2.77 +/- 0.28 h, significantly greater (p less than 0.01) than that in the controls.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),h,2.77,210355,DB01113,Papaverine
,28734159,m/z transitions,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[m] / [z],306.2-164.0,226123,DB01113,Papaverine
,28734159,m/z transitions,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[m] / [z],340.3-202.1,226124,DB01113,Papaverine
,28734159,flow rate,"We utilized multiple reaction monitoring (MRM) at m/z transitions of 306.2-164.0 to analyze CKD-712, and 340.3-202.1 m/z for IS, with a mobile phase of acetonitrile (0.025% trifluoroacetic acid):20mM ammonium acetate (94:6, v/v) at a flow rate of 0.25mL/min.",Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28734159/),[ml] / [min],0.25,226125,DB01113,Papaverine
better,19070586,recoveries,The average recoveries in plasma samples both were better than 85%.,Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070586/),%,85,233288,DB01113,Papaverine
,8980918,absolute bioavailability,The absolute bioavailability was variable and ranged from 24.5-91% with a mean of 58.2 +/- 18.2% (mean +/- SD).,Pharmacokinetics and bioavailability of drotaverine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980918/),%,58.2,233528,DB01113,Papaverine
,1932615,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.","Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932615/),%,57.2,240790,DB01113,Papaverine
,1932615,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.","Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932615/),%,25.2,240791,DB01113,Papaverine
,1932615,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.","Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932615/),%,53.2,240792,DB01113,Papaverine
,1932615,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.","Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932615/),%,3.2,240793,DB01113,Papaverine
,1932615,absolute bioavailability,"The absolute bioavailability of papaverine HCl was determined to be 57.2 per cent, 25.2 per cent, 53.2 per cent, 3.2 per cent and 7.5 per cent, respectively, following P.O., rectal, vaginal, topical and buccal administration.","Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932615/),%,7.5,240794,DB01113,Papaverine
,11124230,apparent K(m),"The uptake of YH1885 into the Caco-2 cell monolayer was saturable and appeared to be mediated by a high-affinity transporter, with an apparent K(m) of 1.47+/-0.21 microM and a V(max) of 25.14+/-1.16 pmol/cm(2)/40 s.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),μM,1.47,243221,DB01113,Papaverine
,11124230,V(max),"The uptake of YH1885 into the Caco-2 cell monolayer was saturable and appeared to be mediated by a high-affinity transporter, with an apparent K(m) of 1.47+/-0.21 microM and a V(max) of 25.14+/-1.16 pmol/cm(2)/40 s.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),[pM] / [40·cm(2)·s],25.14,243222,DB01113,Papaverine
,11124230,solubility,"Saturation of this transport system, in addition to the limited solubility of YH1885 (i.e., approximately 5.3 microM), appears to contribute to the dose-dependent bioavailability of the drug.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),μM,5.3,243223,DB01113,Papaverine
,16580169,specific quantum yields,"The specific quantum yields are equal 0.28, 0.30 and 0.10 for 1 HCl, 2 and 3, respectively which confirm the above stability pattern of the compounds concerned.",Kinetics of photooxidation of papaverine hydrochloride and its major photooxidation products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580169/),,0.28,261398,DB01113,Papaverine
,16580169,specific quantum yields,"The specific quantum yields are equal 0.28, 0.30 and 0.10 for 1 HCl, 2 and 3, respectively which confirm the above stability pattern of the compounds concerned.",Kinetics of photooxidation of papaverine hydrochloride and its major photooxidation products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580169/),,0.30,261399,DB01113,Papaverine
,16580169,specific quantum yields,"The specific quantum yields are equal 0.28, 0.30 and 0.10 for 1 HCl, 2 and 3, respectively which confirm the above stability pattern of the compounds concerned.",Kinetics of photooxidation of papaverine hydrochloride and its major photooxidation products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580169/),,0.10,261400,DB01113,Papaverine
